Literature DB >> 14052980

A PREVENTIVE APPROACH TO IMPETIGO OF TREATY INDIANS USING STAPHYLOCOCCUS POLYVALENT SOMATIC ANTIGEN VACCINE.

H DILLENBERG, M P WALDRON.   

Abstract

In a controlled study, Greenberg's staphylococcal polyvalent somatic antigen vaccine was administered to 190 Indian volunteers of a reserve in Saskatchewan in an attempt to reduce the incidence of impetigo. An intradermal skin test dose of 0.1 ml. was given initially. Reactors were forthwith placed in a separate category, otherwise this test injection was followed by intramuscular injection of 0.25 ml. of the vaccine, repeated a second time after six weeks. One hundred and sixty-nine controls received "placebo vaccine". Four months later the number of cases of impetigo in the vaccinated group had been reduced from 55 to 16. There was no reduction in the control group. The preventive effect waned after five months. The results of this field trial are considered encouraging.

Keywords:  CANADA; IMPETIGO; STAPHYLOCOCCUS; VACCINATION

Mesh:

Substances:

Year:  1963        PMID: 14052980      PMCID: PMC1921861     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  3 in total

1.  Staphylococcal enzyme lysed soluble vaccine.

Authors:  L GREENBERG; W H LE RICHE
Journal:  Can J Public Health       Date:  1961-11

2.  Polyvalent somatic antigen for the prevention of staphylococcal infection.

Authors:  L GREENBERG; M Y COOPER
Journal:  Can Med Assoc J       Date:  1960-07-23       Impact factor: 8.262

3.  Staphylococcus polyvalent somatic antigen vaccine. II. An improved method of preparation.

Authors:  L GREENBERG; M Y COOPER; G M HEALY
Journal:  Can Med Assoc J       Date:  1961-04-29       Impact factor: 8.262

  3 in total
  2 in total

1.  Staphylococcus vaccines.

Authors:  L Greenberg
Journal:  Bull N Y Acad Med       Date:  1968-10

2.  A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge.

Authors:  A I Fattom; J Sarwar; A Ortiz; R Naso
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.